Journal
VACCINE
Volume 34, Issue 50, Pages 6158-6165Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.11.003
Keywords
Cost-effectiveness analysis; PPSV23; Pneumococcal disease; Vaccine
Categories
Funding
- Fourth Round of the Three-year Action Plan on Public Health Discipline and Talent Program (Evidence-based Public Health and Health Economics) [15GWZK0901, 15GWZK0701]
- Overseas Study Project of the Shanghai Health Bureau's Third Round of the Public Health Action Plan [GWHW201213]
- Shanghai Clinical Key Specialty of Clinical Pharmacy (Ren Ji Project)
- National Natural Science Foundation of China [71373160]
Ask authors/readers for more resources
Background: To evaluate the cost-effectiveness of adding 23-valent pneumococcal polysaccharide vaccine (PPSV23) to the immunization schedule for the elderly population (age > 60 years) in Shanghai, China. Methods: A decision-tree model, with data and assumptions adapted from the societal perspective of Shanghai City, was developed to project the health outcomes of PPSV23 vaccination (compared with no vaccination) over a lifetime course. Sensitivity analysis was used to test the model's robustness. The clinical data, utility and treatment costs related to pneumococcal diseases were either cited from the literature or calculated from local sources. Results: The incremental cost-effectiveness ratio of PPSV23 vaccination compared with no vaccination was $16,699/quality-adjusted life years gained, which was lower than the per capita GDP of Shanghai ($16,840). Sensitivity analyses showed that the model's outcome is robust. Conclusions: Routine vaccination of the elderly population with PPSV23 is cost-effective in Shanghai, China. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available